Olumiant Tablet Description
Olumiant (baricitinib) is an oral, once-daily, JAK1/JAK2 inhibitor, approved in the USA, and 70 other countries as a treatment for adults with moderately to severely active rheumatoid arthritis
It is hypothesized that through JAK1 and JAK2 inhibition, baricitinib may reduce the cytokine storm associated with the complications of COVID-19 infection.
In addition, baricitinib may have a role in inhibiting the host cell proteins that assist in viral reproduction, reducing the ability of infected cells to make more viruses.
Olumiant Tablet Indication
Olumiant Tablet is currently approved for treatment for adults with moderately to severely active rheumatoid arthritis
Olumiant Tablet News
June 15, 2020 - Eli Lilly and Company announced that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor
April 10, 2020 - Eli Lilly and Company announced it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to study baricitinib as an arm in NIAID's Adaptive COVID-19 Treatment Trial
Olumiant Tablet Clinical Trials
Clinical Trial NCT04421027: A Study of Baricitinib (LY3009104) in Participants With COVID-19 (COV-BARRIER)
This Phase 3 study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.